Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST Entrectinib substudy for NTRK- or ROS1-altered advanced cancers
ACTRN12621000284864Phase 2Withdrawn
- Sponsor
- The University of Sydney
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entrectinib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and cancer, sponsored by The University of Sydney. Primary endpoints: Objective tumor response and Ratio to time to progression. Planned start Jun 2023; status: withdrawn.
02
Drugs
entrectinib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)cancer
Beyond the preview
Go deeper on ACTRN12621000284864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000284864.